Organogenesis Holdings Inc. (ORGO) jumped 53.72% to $5.98, up $2.09, after reporting strong third-quarter 2025 results and revising its full-year outlook.
The company posted $150.5 million in net product revenue, up 31 percent year-over-year, driven by Advanced Wound Care, up 31 percent, and Surgical & Sports Medicine, up 25 percent.
Net income reached $21.6 million, or $0.11 per share, versus $12.3 million and $0.09 per share in the year-ago period; adjusted EBITDA rose to $30.1 million, more than double the prior year.
For full-year 2025, the company raised guidance: expecting $500 million-$525 million in net product revenue, a 4-9 percent growth, and adjusted EBITDA of $45.5 million-$68.3 million.
On the earnings day, ORGO's volume spiked as the market reacted to the beat and guidance bump. The stock's 52-week range is approximately $2.61 - $6.71.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.